Immune evasion by Kaposi's sarcoma-associated herpesvirus

Future Microbiology

Volumn 5, Issue 9, 2010, Pages 1349-1365

  Lee, Hye Ra ^a   Lee, Stacy ^a   Chaudhary, Preet M ^a   Gill, Parkash ^a   Jung, Jae U ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

immune evasion; immune modulatory protein; Kaposi's sarcoma; Kaposis sarcoma associated herpesvirus; primary effusion lymphoma

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; CCL1 CHEMOKINE; CD200 ANTIGEN; CHEMOKINE RECEPTOR CCR1; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR1; CHEMOKINE RECEPTOR CXCR4; FLICE INHIBITORY PROTEIN; G PROTEIN COUPLED RECEPTOR; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTEIN BCL 2; RANTES; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; TOLL LIKE RECEPTOR 6; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 9;

ADAPTIVE IMMUNITY; ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; ANTIGEN PRESENTATION; APOPTOSIS; AUTOPHAGY; CD4+ CD25+ T LYMPHOCYTE; CELLULAR IMMUNITY; COMPLEMENT SYSTEM; HERPES VIRUS; HERPES VIRUS INFECTION; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNE SYSTEM; INFLAMMATION; INNATE IMMUNITY; KAPOSI SARCOMA; PATHOGENESIS; PRIMARY EFFUSION LYMPHOMA; PRIORITY JOURNAL; REVIEW; VIRUS REPLICATION;

ANIMALS; HERPESVIRUS 8, HUMAN; HUMANS; IMMUNE EVASION; LYMPHOMA, PRIMARY EFFUSION; MICE; SARCOMA, KAPOSI;

HERPESVIRIDAE; HUMAN HERPESVIRUS 8;

EID: 77957596318     PISSN: 17460913     EISSN: None     Source Type: Journal    
DOI: 10.2217/fmb.10.105     Document Type: Review

References (201)

1. Chang Y, Cesarman E, Pessin MS et al.: Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposis sarcoma. Science 266(5192), 1865-1869 (1994).
2. Jung JU, Choi JK, Ensser A, Biesinger B: Herpesvirus saimiri as a model for gammaherpesvirus oncogenesis. Semin. Cancer Biol. 9(3), 231-239 (1999).
3. Alexander L, Denekamp L, Knapp A, Auerbach MR, Damania B, Desrosiers RC: The primary sequence of rhesus monkey rhadinovirus isolate 26-95: sequence similarities to Kaposis sarcoma-associated herpesvirus and rhesus monkey rhadinovirus isolate 17577. J. Virol. 74(7), 3388-3398 (2000).
4. Russo JJ, Bohenzky RA, Chien MC et al.: Nucleotide sequence of the Kaposi sarcoma-associated herpesvirus (HHV8). Proc. Natl Acad. Sci. USA 93(25), 14862-14867 (1996).
5. Neipel F, Albrecht JC, Fleckenstein B: Cell-homologous genes in the Kaposis sarcoma-associated rhadinovirus human herpesvirus 8: determinants of its pathogenicity? J. Virol. 71(6), 4187-4192 (1997).
6. Albrecht JC, Nicholas J, Biller D et al.: Primary structure of the Herpesvirus saimiri genome. J. Virol. 66(8), 5047-5058 (1992).
7. Wang FZ, Akula SM, Sharma-Walia N, Zeng L, Chandran B: Human herpesvirus 8 envelope glycoprotein B mediates cell adhesion via its RGD sequence. J. Virol. 77(5), 3131-3147 (2003).
8. Akula SM, Wang FZ, Vieira J, Chandran B: Human herpesvirus 8 interaction with target cells involves heparan sulfate. Virology 282(2), 245-255 (2001).
9. Birkmann A, Mahr K, Ensser A et al.: Cell surface heparan sulfate is a receptor for human herpesvirus 8 and interacts with envelope glycoprotein K8.1. J. Virol. 75(23), 11583-11593 (2001).
10. Pertel PE: Human herpesvirus 8 glycoprotein B (gB), gH, and gL can mediate cell fusion. J. Virol. 76(9), 4390-4400 (2002).
11. Kaleeba JA, Berger EA: Kaposis sarcoma-associated herpesvirus fusion-entry receptor: cystine transporter xCT. Science 311(5769), 1921-1924 (2006).
12. Sun R, Lin SF, Gradoville L, Yuan Y, Zhu F, Miller G: A viral gene that activates lytic cycle expression of Kaposis sarcoma-associated herpesvirus. Proc. Natl Acad. Sci. USA 95(18), 10866-10871 (1998).
13. Gradoville L, Gerlach J, Grogan E et al.: Kaposis sarcoma-associated herpesvirus open reading frame 50/Rta protein activates the entire viral lytic cycle in the HH-B2 primary effusion lymphoma cell line. J. Virol. 74(13), 6207-6212 (2000).
14. Lukac DM, Renne R, Kirshner JR, Ganem D: Reactivation of Kaposis sarcoma-associated herpesvirus infection from latency by expression of the ORF 50 transactivator, a homolog of the EBV R protein. Virology 252(2), 304-312 (1998).
15. Renne R, Zhong W, Herndier B et al.: Lytic growth of Kaposis sarcoma-associated herpesvirus (human herpesvirus 8) in culture. Nat. Med. 2(3), 342-346 (1996).
16. Duprez R, Lacoste V, Briere J et al.: Evidence for a multiclonal origin of multicentric advanced lesions of Kaposi sarcoma. J. Natl Cancer Inst. 99(14), 1086-1094 (2007).
17. Samols MA, Hu J, Skalsky RL, Renne R: Cloning and identification of a microRNA cluster within the latency-associated region of Kaposis sarcoma-associated herpesvirus. J. Virol. 79(14), 9301-9305 (2005).
18. Cai X, Lu S, Zhang Z, Gonzalez CM, Damania B, Cullen BR: Kaposis sarcoma-associated herpesvirus expresses an array of viral microRNAs in latently infected cells. Proc. Natl Acad. Sci. USA 102(15), 5570-5575 (2005).
19. Grundhoff A, Sullivan CS, Ganem D: A combined computational and microarray-based approach identifies novel microRNAs encoded by human g-herpesviruses. RNA 12(5), 733-750 (2006).
20. Pfeffer S, Sewer A, Lagos-Quintana M et al.: Identification of microRNAs of the herpesvirus family. Nat. Methods 2(4), 269-276 (2005).
21. Cai X, Cullen BR: Transcriptional origin of Kaposis sarcoma-associated herpesvirus microRNAs. J. Virol. 80(5), 2234-2242 (2006).
22. Lu F, Stedman W, Yousef M, Renne R, Lieberman PM: Epigenetic regulation of Kaposis sarcoma-associated herpesvirus latency by virus-encoded microRNAs that target Rta and the cellular Rbl2-DNMT pathway. J. Virol. 84(6), 2697-2706 (2010)
23. Lei X, Bai Z, Ye F et al.: Regulation of NF-kB inhibitor IkBa and viral replication by a KSHV microRNA. Nat. Cell Biol. 12(2), 193-199 (2010).
24. Bellare P, Ganem D: Regulation of KSHV lytic switch protein expression by a virus-encoded microRNA: an evolutionary adaptation that fine-tunes lytic reactivation. Cell Host Microbe 6(6), 570-575 (2009).
25. Marshall V, Parks T, Bagni R et al.: Conservation of virally encoded microRNAs in Kaposi sarcoma-associated herpesvirus in primary effusion lymphoma cell lines and in patients with Kaposi sarcoma or multicentric Castleman disease. J. Infect. Dis. 195(5), 645-659 (2007).
26. Sun R, Lin SF, Gradoville L, Miller G: Polyadenylylated nuclear RNA encoded by Kaposi sarcoma-associated herpesvirus. Proc. Natl Acad. Sci. USA 93(21), 11883-11888 (1996).
27. Conrad NK, Steitz JA: A Kaposis sarcoma virus RNA element that increases the nuclear abundance of intronless transcripts. EMBO J. 24(10), 1831-1841 (2005).
28. Morgan BP, Marchbank KJ, Longhi MP, Harris CL, Gallimore AM: Complement: central to innate immunity and bridging to adaptive responses. Immunol. Lett. 97(2), 171-179 (2005).
29. Dunkelberger JR, Song WC: Complement and its role in innate and adaptive immune responses. Cell Res. 20(1), 34-50 (2010).
30. Blom AM: Strategies developed by bacteria and virus for protection from the human complement system. Scand. J. Clin. Lab. Invest. 64(5), 479-496 (2004).
31. Spiller OB, Robinson M, ODonnell E et al.: Complement regulation by Kaposis sarcoma-associated herpesvirus ORF4 protein. J. Virol. 77(1), 592-599 (2003).
32. Fodor WL, Rollins SA, Bianco-Caron S et al.: The complement control protein homolog of Herpesvirus saimiri regulates serum complement by inhibiting C3 convertase activity. J. Virol. 69(6), 3889-3892 (1995).
33. Kapadia SB, Molina H, van Berkel V, Speck SH, Virgin HW IV: Murine gammaherpesvirus 68 encodes a functional regulator of complement activation. J. Virol. 73(9), 7658-7670 (1999).
34. Okroj M, Mark L, Stokowska A et al.: Characterization of the complement inhibitory function of rhesus rhadinovirus complement control protein (RCP). J. Biol. Chem. 284(1), 505-514 (2009).
35. Isaacs A, Lindenmann J: Virus interference. I. The interferon. Proc. R. Soc. Lond. B Biol. Sci. 147(927), 258-267 (1957).
36. Pestka S, Krause CD, Walter MR: Interferons, interferon-like cytokines, and their receptors. Immunol. Rev. 202, 8-32 (2004).
37. Muller U, Steinhoff U, Reis LF et al.: Functional role of type I and type II interferons in antiviral defense. Science 264(5167), 1918-1921 (1994).
38. Weber F, Kochs G, Haller O: Inverse interference: how viruses fight the interferon system. Viral Immunol. 17(4), 498-515 (2004).
39. Dupuis S, Jouanguy E, Al-Hajjar S et al.: Impaired response to interferon-a/b and lethal viral disease in human STAT1 deficiency. Nat. Genet. 33(3), 388-391 (2003).
40. Samuel CE: Antiviral actions of interferons. Clin. Microbiol. Rev. 14(4), 778-809 (2001).
41. Moore PS, Boshoff C, Weiss RA, Chang Y: Molecular mimicry of human cytokine and cytokine response pathway genes by KSHV. Science 274(5293), 1739-1744 (1996).
42. Jenner RG, Alba MM, Boshoff C, Kellam P: Kaposis sarcoma-associated herpesvirus latent and lytic gene expression as revealed by DNA arrays. J. Virol. 75(2), 891-902 (2001).
43. Parravicini C, Chandran B, Corbellino M et al.: Differential viral protein expression in Kaposis sarcoma-associated herpesvirus-infected diseases: Kaposis sarcoma, primary effusion lymphoma, and multicentric Castlemans disease. Am. J. Pathol. 156(3), 743-749 (2000).
44. Dittmer DP: Transcription profile of Kaposis sarcoma-associated herpesvirus in primary Kaposis sarcoma lesions as determined by real-time PCR arrays. Cancer Res. 63(9), 2010-2015 (2003).
45. Rivas C, Thlick AE, Parravicini C, Moore PS, Chang Y: Kaposis sarcoma-associated herpesvirus LANA2 is a B-cell-specific latent viral protein that inhibits p53. J. Virol. 75(1), 429-438 (2001).
46. Cunningham C, Barnard S, Blackbourn DJ, Davison AJ: Transcription mapping of human herpesvirus 8 genes encoding viral interferon regulatory factors. J. Gen. Virol. 84(Pt 6), 1471-1483 (2003).
47. Lee HR, Kim MH, Lee JS, Liang C, Jung JU: Viral interferon regulatory factors. J. Interferon Cytokine Res. 29(9), 621-627 (2009).
48. Takaoka A, Tamura T, Taniguchi T: Interferon regulatory factor family of transcription factors and regulation of oncogenesis. Cancer Sci. 99(3), 467-478 (2008).
49. Flowers CC, Flowers SP, Nabel GJ: Kaposis sarcoma-associated herpesvirus viral interferon regulatory factor confers resistance to the antiproliferative effect of interferon-a. Mol. Med. 4(6), 402-412 (1998).
50. Zimring JC, Goodbourn S, Offermann MK: Human herpesvirus 8 encodes an interferon regulatory factor (IRF) homolog that represses IRF-1-mediated transcription. J. Virol. 72(1), 701-707 (1998).
51. Tamura T, Yanai H, Savitsky D, Taniguchi T: The IRF family transcription factors in immunity and oncogenesis. Annu. Rev. Immunol. 26, 535-584 (2008).
52. Park J, Lee MS, Yoo SM et al.: Identification of the DNA sequence interacting with Kaposis sarcoma-associated herpesvirus viral interferon regulatory factor 1. J. Virol. 81(22), 12680-12684 (2007).
53. Burysek L, Yeow WS, Lubyova B et al.: Functional analysis of human herpesvirus 8-encoded viral interferon regulatory factor 1 and its association with cellular interferon regulatory factors and p300. J. Virol. 73(9), 7334-7342 (1999).
54. Li M, Lee H, Guo J et al.: Kaposis sarcoma-associated herpesvirus viral interferon regulatory factor. J. Virol. 72(7), 5433-5440 (1998).
55. Li M, Damania B, Alvarez X, Ogryzko V, Ozato K, Jung JU: Inhibition of p300 histone acetyltransferase by viral interferon regulatory factor. Mol. Cell Biol. 20(21), 8254-8263 (2000).
56. Lin R, Genin P, Mamane Y et al.: HHV-8 encoded vIRF-1 represses the interferon antiviral response by blocking IRF-3 recruitment of the CBP/p300 coactivators. Oncogene 20(7), 800-811 (2001).
57. Fuld S, Cunningham C, Klucher K, Davison AJ, Blackbourn DJ: Inhibition of interferon signaling by the Kaposis sarcoma-associated herpesvirus full-length viral interferon regulatory factor 2 protein. J. Virol. 80(6), 3092-3097 (2006).
58. Areste C, Mutocheluh M, Blackbourn DJ: Identification of caspase-mediated decay of interferon regulatory factor-3, exploited by a Kaposi sarcoma-associated herpesvirus immunoregulatory protein. J. Biol. Chem. 284(35), 23272-23285 (2009).
59. Burysek L, Pitha PM: Latently expressed human herpesvirus 8-encoded interferon regulatory factor 2 inhibits double-stranded RNA-activated protein kinase. J. Virol. 75(5), 2345-2352 (2001).
60. Burysek L, Yeow WS, Pitha PM: Unique properties of a second human herpesvirus 8-encoded interferon regulatory factor (vIRF-2). J. Hum. Virol. 2(1), 19-32 (1999).
61. Joo CH, Shin YC, Gack M, Wu L, Levy D, Jung JU: Inhibition of interferon regulatory factor 7 (IRF7)-mediated interferon signal transduction by the Kaposis sarcoma-associated herpesvirus viral IRF homolog vIRF3. J. Virol. 81(15), 8282-8292 (2007).
62. Wies E, Hahn AS, Schmidt K et al.: The Kaposis Sarcoma-associated herpesvirus-encoded vIRF-3 inhibits cellular IRF-5. J. Biol. Chem. 284(13), 8525-8538 (2009).
63. Wies E, Mori Y, Hahn A et al.: The viral interferon-regulatory factor-3 is required for the survival of KSHV-infected primary effusion lymphoma cells. Blood 111(1), 320-327 (2008).
64. Cloutier N, Flamand L: Kaposi sarcoma-associated herpesvirus latency-associated nuclear antigen inhibits interferon (IFN) b expression by competing with IFN regulatory factor-3 for binding to IFNB promoter. J. Biol. Chem. 285(10), 7208-7221 (2010).
65. Lefort S, Soucy-Faulkner A, Grandvaux N, Flamand L: Binding of Kaposis sarcoma-associated herpesvirus K-bZIP to interferon-responsive factor 3 elements modulates antiviral gene expression. J. Virol. 81(20), 10950-10960 (2007).
66. Zhu FX, King SM, Smith EJ, Levy DE, Yuan Y: A Kaposis sarcoma-associated herpesviral protein inhibits virus-mediated induction of type I interferon by blocking IRF-7 phosphorylation and nuclear accumulation. Proc. Natl Acad. Sci. USA 99(8), 5573-5578 (2002).
67. Yu Y, Wang SE, Hayward GS: The KSHV immediate-early transcription factor RTA encodes ubiquitin E3 ligase activity that targets IRF7 for proteosome-mediated degradation. Immunity 22(1), 59-70 (2005).
68. Baggiolini M: Chemokines and leukocyte traffic. Nature 392(6676), 565-568 (1998).
69. Fernandez EJ, Lolis E: Structure, function, and inhibition of chemokines. Annu. Rev. Pharmacol. Toxicol. 42, 469-499 (2002).
70. Ransohoff RM: Chemokines and chemokine receptors: standing at the crossroads of immunobiology and neurobiology. Immunity 31(5), 711-721 (2009).
71. Laing KJ, Secombes CJ: Chemokines. Dev. Comp. Immunol. 28(5), 443-460 (2004).
72. McFadden G, Murphy PM: Host-related immunomodulators encoded by poxviruses and herpesviruses. Curr. Opin. Microbiol. 3(4), 371-378 (2000).
73. Murphy PM: Viral exploitation and subversion of the immune system through chemokine mimicry. Nat. Immunol. 2(2), 116-122 (2001).
74. Sozzani S, Luini W, Bianchi G et al.: The viral chemokine macrophage inflammatory protein-II is a selective Th2 chemoattractant. Blood 92(11), 4036-4039 (1998).
75. Stine JT, Wood C, Hill M et al.: KSHV-encoded CC chemokine vMIP-III is a CCR4 agonist, stimulates angiogenesis, and selectively chemoattracts TH2 cells. Blood 95(4), 1151-1157 (2000).
76. Dairaghi DJ, Fan RA, McMaster BE, Hanley MR, Schall TJ: HHV8-encoded vMIP-I selectively engages chemokine receptor CCR8. Agonist and antagonist profiles of viral chemokines. J. Biol. Chem. 274(31), 21569-21574 (1999).
77. Iellem A, Mariani M, Lang R et al.: Unique chemotactic response profile and specific expression of chemokine receptors CCR4 and CCR8 by CD4(+)CD25(+) regulatory T cells. J. Exp. Med. 194(6), 847-853 (2001).
78. Kledal TN, Rosenkilde MM, Coulin F et al.: A broad-spectrum chemokine antagonist encoded by Kaposis sarcoma-associated herpesvirus. Science 277(5332), 1656-1659 (1997).
79. Weber KS, Grone HJ, Rocken M et al.: Selective recruitment of Th2-type cells and evasion from a cytotoxic immune response mediated by viral macrophage inhibitory protein-II. Eur. J. Immunol. 31(8), 2458-2466 (2001).
80. Chen S, Bacon KB, Li L et al.: In vivo inhibition of CC and CX3C chemokine-induced leukocyte infiltration and attenuation of glomerulonephritis in Wistar-Kyoto (WKY) rats by vMIP-II. J. Exp. Med. 188(1), 193-198 (1998).
81. Liu C, Okruzhnov Y, Li H, Nicholas J: Human herpesvirus 8 (HHV-8)-encoded cytokines induce expression of and autocrine signaling by vascular endothelial growth factor (VEGF) in HHV-8-infected primary-effusion lymphoma cell lines and mediate VEGF-independent antiapoptotic effects. J. Virol. 75(22), 10933-10940 (2001).
82. Choi YB, Nicholas J: Induction of angiogenic chemokine CCL2 by human herpesvirus 8 chemokine receptor. Virology 397(2), 369-378 (2010).
83. Chung YH, Means RE, Choi JK, Lee BS, Jung JU: Kaposis sarcoma-associated herpesvirus OX2 glycoprotein activates myeloid-lineage cells to induce inflammatory cytokine production. J. Virol. 76(10), 4688-4698 (2002).
84. Wright GJ, Cherwinski H, Foster-Cuevas M et al.: Characterization of the CD200 receptor family in mice and humans and their interactions with CD200. J. Immunol. 171(6), 3034-3046 (2003).
85. Rijkers ES, de Ruiter T, Baridi A, Veninga H, Hoek RM, Meyaard L: The inhibitory CD200R is differentially expressed on human and mouse T and B lymphocytes. Mol. Immunol. 45(4), 1126-1135 (2008).
86. Minas K, Liversidge J: Is the CD200/CD200 receptor interaction more than just a myeloid cell inhibitory signal? Crit. Rev. Immunol. 26(3), 213-230 (2006).
87. Foster-Cuevas M, Wright GJ, Puklavec MJ, Brown MH, Barclay AN: Human herpesvirus 8 K14 protein mimics CD200 in down-regulating macrophage activation through CD200 receptor. J. Virol. 78(14), 7667-7676 (2004).
88. Rezaee SA, Gracie JA, McInnes IB, Blackbourn DJ: Inhibition of neutrophil function by the Kaposis sarcoma-associated herpesvirus vOX2 protein. AIDS 19(16), 1907-1910 (2005).
89. Neipel F, Albrecht JC, Ensser A et al.: Human herpesvirus 8 encodes a homolog of interleukin-6. J. Virol. 71(1), 839-842 (1997).
90. Nishimoto N, Kishimoto T: Interleukin 6: from bench to bedside. Nat. Clin. Pract. Rheumatol. 2(11), 619-626 (2006).
91. Molden J, Chang Y, You Y, Moore PS, Goldsmith MA: A Kaposis sarcoma-associated herpesvirus-encoded cytokine homolog (vIL-6) activates signaling through the shared gp130 receptor subunit. J. Biol. Chem. 272(31), 19625-19631 (1997).
92. Breen EC, Gage JR, Guo B et al.: Viral interleukin 6 stimulates human peripheral blood B cells that are unresponsive to human interleukin 6. Cell. Immunol. 212(2), 118-125 (2001).
93. Staskus KA, Sun R, Miller G et al.: Cellular tropism and viral interleukin-6 expression distinguish human herpesvirus 8 involvement in Kaposis sarcoma, primary effusion lymphoma, and multicentric Castlemans disease. J. Virol. 73(5), 4181-4187 (1999).
94. Brousset P, Cesarman E, Meggetto F, Lamant L, Delsol G: Colocalization of the viral interleukin-6 with latent nuclear antigen-1 of human herpesvirus-8 in endothelial spindle cells of Kaposis sarcoma and lymphoid cells of multicentric Castlemans disease. Hum. Pathol. 32(1), 95-100 (2001).
95. Cannon JS, Nicholas J, Orenstein JM et al.: Heterogeneity of viral IL-6 expression in HHV-8-associated diseases. J. Infect. Dis. 180(3), 824-828 (1999).
96. Nicholas J, Ruvolo V, Zong J et al.: A single 13-kilobase divergent locus in the Kaposi sarcoma-associated herpesvirus (human herpesvirus 8) genome contains nine open reading frames that are homologous to or related to cellular proteins. J. Virol. 71(3), 1963-1974 (1997).
97. Chen D, Sandford G, Nicholas J: Intracellular signaling mechanisms and activities of human herpesvirus 8 interleukin-6. J. Virol. 83(2), 722-733 (2009).
98. Aoki Y, Jaffe ES, Chang Y et al.: Angiogenesis and hematopoiesis induced by Kaposis sarcoma-associated herpesvirus-encoded interleukin-6. Blood 93(12), 4034-4043 (1999).
99. Chatterjee M, Osborne J, Bestetti G, Chang Y, Moore PS: Viral IL-6-induced cell proliferation and immune evasion of interferon activity. Science 298(5597), 1432-1435 (2002).
100. Rosenkilde MM, Kledal TN, Brauner-Osborne H, Schwartz TW: Agonists and inverse agonists for the herpesvirus 8-encoded constitutively active seven-transmembrane oncogene product, ORF-74. J. Biol. Chem. 274(2), 956-961 (1999).
101. Bais C, Santomasso B, Coso O et al.: G-protein-coupled receptor of Kaposis sarcoma-associated herpesvirus is a viral oncogene and angiogenesis activator. Nature 391(6662), 86-89 (1998).
102. Sodhi A, Montaner S, Patel V et al.: The Kaposis sarcoma-associated herpes virus G protein-coupled receptor up-regulates vascular endothelial growth factor expression and secretion through mitogen-activated protein kinase and p38 pathways acting on hypoxia-inducible factor 1a. Cancer Res. 60(17), 4873-4880 (2000).
103. Montaner S, Sodhi A, Pece S, Mesri EA, Gutkind JS: The Kaposis sarcoma-associated herpesvirus G protein-coupled receptor promotes endothelial cell survival through the activation of Akt/protein kinase B. Cancer Res. 61(6), 2641-2648 (2001).
104. Bais C, Van Geelen A, Eroles P et al.: Kaposis sarcoma associated herpesvirus G protein-coupled receptor immortalizes human endothelial cells by activation of the VEGF receptor-2/ KDR. Cancer Cell 3(2), 131-143 (2003).
105. Arvanitakis L, Geras-Raaka E, Varma A, Gershengorn MC, Cesarman E: Human herpesvirus KSHV encodes a constitutively active G-protein-coupled receptor linked to cell proliferation. Nature 385(6614), 347-350 (1997).
106. Virgin HW, Latreille P, Wamsley P et al.: Complete sequence and genomic analysis of murine gammaherpesvirus 68. J. Virol. 71(8), 5894-5904 (1997).
107. Paulsen SJ, Rosenkilde MM, Eugen-Olsen J, Kledal TN: Epstein-Barr virus-encoded BILF1 is a constitutively active G protein-coupled receptor. J. Virol. 79(1), 536-546 (2005).
108. Davis-Poynter NJ, Lynch DM, Vally H et al.: Identification and characterization of a G protein-coupled receptor homolog encoded by murine cytomegalovirus. J. Virol. 71(2), 1521-1529 (1997).
109. Paulose-Murphy M, Ha NK, Xiang C et al.: Transcription program of human herpesvirus 8 (kaposis sarcoma-associated herpesvirus). J. Virol. 75(10), 4843-4853 (2001).
110. Beisser PS, Grauls G, Bruggeman CA, Vink C: Deletion of the R78 G protein-coupled receptor gene from rat cytomegalovirus results in an attenuated, syncytium-inducing mutant strain. J. Virol. 73(9), 7218-7230 (1999).
111. McFadden G, Lalani A, Everett H, Nash P, Xu X: Virus-encoded receptors for cytokines and chemokines. Semin. Cell Dev. Biol. 9(3), 359-368 (1998).
112. Parry CM, Simas JP, Smith VP et al.: A broad spectrum secreted chemokine binding protein encoded by a herpesvirus. J. Exp. Med. 191(3), 573-578 (2000).
113. Webb LM, Alcami A: Virally encoded chemokine binding proteins. Mini Rev. Med. Chem. 5(9), 833-848 (2005).
114. Seet BT, McFadden G: Viral chemokine-binding proteins. J. Leukoc. Biol. 72(1), 24-34 (2002).
115. Carfi A, Smith CA, Smolak PJ, McGrew J, Wiley DC: Structure of a soluble secreted chemokine inhibitor vCCI (p35) from cowpox virus. Proc. Natl Acad. Sci. USA 96(22), 12379-12383 (1999).
116. Danial NN, Korsmeyer SJ: Cell death: critical control points. Cell 116(2), 205-219 (2004).
117. Green DR: Apoptotic pathways: ten minutes to dead. Cell 121(5), 671-674 (2005).
118. Maiuri MC, Zalckvar E, Kimchi A, Kroemer G: Self-eating and self-killing: crosstalk between autophagy and apoptosis. Nat. Rev. Mol. Cell Biol. 8(9), 741-752 (2007).
119. Levine B, Yuan J: Autophagy in cell death: an innocent convict? J. Clin. Invest. 115(10), 2679-2688 (2005).
120. Thorburn J, Moore F, Rao A et al.: Selective inactivation of a Fas-associated death domain protein (FADD)-dependent apoptosis and autophagy pathway in immortal epithelial cells. Mol. Biol. Cell 16(3), 1189-1199 (2005).
121. Mills KR, Reginato M, Debnath J, Queenan B, Brugge JS: Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is required for induction of autophagy during lumen formation in vitro. Proc. Natl Acad. Sci. USA 101(10), 3438-3443 (2004).
122. Levine B: Eating oneself and uninvited guests: autophagy-related pathways in cellular defense. Cell 120(2), 159-162 (2005).
123. Arico S, Petiot A, Bauvy C et al.: The tumor suppressor PTEN positively regulates macroautophagy by inhibiting the phosphatidylinositol 3-kinase/protein kinase B pathway. J. Biol. Chem. 276(38), 35243-35246 (2001).
124. Jia L, Dourmashkin RR, Allen PD, Gray AB, Newland AC, Kelsey SM: Inhibition of autophagy abrogates tumour necrosis factor a induced apoptosis in human T-lymphoblastic leukaemic cells. Br. J. Haematol. 98(3), 673-685 (1997).
125. Lum JJ, DeBerardinis RJ, Thompson CB: Autophagy in metazoans: cell survival in the land of plenty. Nat. Rev. Mol. Cell Biol. 6(6), 439-448 (2005).
126. Feng Z, Zhang H, Levine AJ, Jin S: The coordinate regulation of the p53 and mTOR pathways in cells. Proc. Natl Acad. Sci. USA 102(23), 8204-8209 (2005).
127. Pyo JO, Jang MH, Kwon YK et al.: Essential roles of Atg5 and FADD in autophagic cell death: dissection of autophagic cell death into vacuole formation and cell death. J. Biol. Chem. 280(21), 20722-20729 (2005).
128. Fakhari FD, Dittmer DP: Charting latency transcripts in Kaposis sarcoma-associated herpesvirus by whole-genome real-time quantitative PCR. J. Virol. 76(12), 6213-6223 (2002).
129. Dittmer D, Lagunoff M, Renne R, Staskus K, Haase A, Ganem D: A cluster of latently expressed genes in Kaposis sarcoma-associated herpesvirus. J. Virol. 72(10), 8309-8315 (1998).
130. Grundhoff A, Ganem D: Mechanisms governing expression of the v-FLIP gene of Kaposis sarcoma-associated herpesvirus. J. Virol. 75(4), 1857-1863 (2001).
131. Bieleski L, Talbot SJ: Kaposis sarcoma-associated herpesvirus vCyclin open reading frame contains an internal ribosome entry site. J. Virol. 75(4), 1864-1869 (2001).
132. Low W, Harries M, Ye H, Du MQ, Boshoff C, Collins M: Internal ribosome entry site regulates translation of Kaposis sarcoma-associated herpesvirus FLICE inhibitory protein. J. Virol. 75(6), 2938-2945 (2001).
133. Belanger C, Gravel A, Tomoiu A et al.: Human herpesvirus 8 viral FLICE-inhibitory protein inhibits Fas-mediated apoptosis through binding and prevention of procaspase-8 maturation. J. Hum. Virol. 4(2), 62-73 (2001).
134. Chaudhary PM, Jasmin A, Eby MT, Hood L: Modulation of the NF-k B pathway by virally encoded death effector domains-containing proteins. Oncogene 18(42), 5738-5746 (1999).
135. Liu L, Eby MT, Rathore N, Sinha SK, Kumar A, Chaudhary PM: The human herpes virus 8-encoded viral FLICE inhibitory protein physically associates with and persistently activates the IkB kinase complex. J. Biol. Chem. 277(16), 13745-13751 (2002).
136. Field N, Low W, Daniels M et al.: KSHV vFLIP binds to IKK-g to activate IKK. J. Cell. Sci. 116(Pt 18), 3721-3728 (2003).
137. Chugh P, Matta H, Schamus S et al.: Constitutive NF-kB activation, normal Fas-induced apoptosis, and increased incidence of lymphoma in human herpes virus 8 K13 transgenic mice. Proc. Natl Acad. Sci. USA 102(36), 12885-12890 (2005).
138. Grossmann C, Podgrabinska S, Skobe M, Ganem D: Activation of NF-kB by the latent vFLIP gene of Kaposis sarcoma-associated herpesvirus is required for the spindle shape of virus-infected endothelial cells and contributes to their proinflammatory phenotype. J. Virol. 80(14), 7179-7185 (2006).
139. Sun Q, Matta H, Lu G, Chaudhary PM: Induction of IL-8 expression by human herpesvirus 8 encoded vFLIP K13 via NF-kB activation. Oncogene 25(19), 2717-2726 (2006).
140. Ye FC, Zhou FC, Xie JP et al.: Kaposis sarcoma-associated herpesvirus latent gene vFLIP inhibits viral lytic replication through NF-kB-mediated suppression of the AP-1 pathway: a novel mechanism of virus control of latency. J. Virol. 82(9), 4235-4249 (2008).
141. Zhao J, Punj V, Matta H et al.: K13 blocks KSHV lytic replication and deregulates vIL6 and hIL6 expression: a model of lytic replication induced clonal selection in viral oncogenesis. PLoS One 2(10), E1067 (2007).
142. Sun Q, Zachariah S, Chaudhary PM: The human herpes virus 8-encoded viral FLICE-inhibitory protein induces cellular transformation via NF-kB activation. J. Biol. Chem. 278(52), 52437-52445 (2003).
143. Lee JS, Li Q, Lee JY et al.: FLIP-mediated autophagy regulation in cell death control. Nat. Cell Biol. 11(11), 1355-1362 (2009).
144. Korsmeyer SJ: BCL-2 gene family and the regulation of programmed cell death. Cancer Res. 59(7 Suppl.), S1693-S1700 (1999).
145. Cheng EH, Nicholas J, Bellows DS et al.: A Bcl-2 homolog encoded by Kaposi sarcoma-associated virus, human herpesvirus 8, inhibits apoptosis but does not heterodimerize with Bax or Bak. Proc. Natl Acad. Sci. USA 94(2), 690-694 (1997).
146. Sarid R, Sato T, Bohenzky RA, Russo JJ, Chang Y: Kaposis sarcoma-associated herpesvirus encodes a functional Bcl-2 homologue. Nat. Med. 3(3), 293-298 (1997).
147. Huang Q, Petros AM, Virgin HW, Fesik SW, Olejniczak ET: Solution structure of a Bcl-2 homolog from Kaposi sarcoma virus. Proc. Natl Acad. Sci. USA 99(6), 3428-3433 (2002).
148. Polster BM, Pevsner J, Hardwick JM: Viral Bcl-2 homologs and their role in virus replication and associated diseases. Biochim. Biophys. Acta 1644(2-3), 211-227 (2004).
149. Cuconati A, White E: Viral homologs of BCL-2: role of apoptosis in the regulation of virus infection. Genes Dev. 16(19), 2465-2478 (2002).
150. Bellows DS, Chau BN, Lee P, Lazebnik Y, Burns WH, Hardwick JM: Antiapoptotic herpesvirus Bcl-2 homologs escape caspase-mediated conversion to proapoptotic proteins. J. Virol. 74(11), 5024-5031 (2000).
151. Loh J, Huang Q, Petros AM et al.: A surface groove essential for viral Bcl-2 function during chronic infection in vivo. PLoS Pathog. 1(1), E10 (2005).
152. Wang GH, Garvey TL, Cohen JI: The murine gherpesvirus-68 M11 protein inhibits Fas- and TNF-induced apoptosis. J. Gen. Virol. 80 (Pt 10), 2737-2740 (1999).
153. Pattingre S, Tassa A, Qu X et al.: Bcl-2 antiapoptotic proteins inhibit Beclin 1-dependent autophagy. Cell 122(6), 927-939 (2005).
154. Pattingre S, Levine B. Bcl-2 inhibition of autophagy: a new route to cancer? Cancer Res. 66(6), 2885-2888 (2006).
155. Ku B, Woo JS, Liang C et al.: Structural and biochemical bases for the inhibition of autophagy and apoptosis by viral BCL-2 of murine g-herpesvirus 68. PLoS Pathog. 4(2), E25 (2008).
156. Xiaofei E, Hwang S, Oh S et al.: Viral Bcl-2-mediated evasion of autophagy aids chronic infection of gammaherpesvirus 68. PLoS Pathog. 5(10), E1000609 (2009).
157. Akira S, Uematsu S, Takeuchi O: Pathogen recognition and innate immunity. Cell 124(4), 783-801 (2006).
158. Beutler BA: TLRs and innate immunity. Blood 113(7), 1399-1407 (2009).
159. Janeway CA Jr, Medzhitov R: Innate immune recognition. Annu. Rev. Immunol. 20, 197-216 (2002).
160. Kawai T, Akira S: TLR signaling. Semin. Immunol. 19(1), 24-32 (2007).
161. Kumar H, Kawai T, Akira S: Toll-like receptors and innate immunity. Biochem. Biophys. Res. Commun. 388(4), 621-625 (2009).
162. West J, Damania B: Upregulation of the TLR3 pathway by Kaposis sarcoma-associated herpesvirus during primary infection. J. Virol. 82(11), 5440-5449 (2008).
163. Lagos D, Vart RJ, Gratrix F et al.: Toll-like receptor 4 mediates innate immunity to Kaposi sarcoma herpesvirus. Cell Host Microbe 4(5), 470-483 (2008).
164. Gregory SM, West JA, Dillon PJ, Hilscher C, Dittmer DP, Damania B: Toll-like receptor signaling controls reactivation of KSHV from latency. Proc. Natl Acad. Sci. USA 106(28), 11725-11730 (2009).
165. Ambroziak JA, Blackbourn DJ, Herndier BG et al.: Herpes-like sequences in HIV-infected and uninfected Kaposis sarcoma patients. Science 268(5210), 582-583 (1995).
166. Wilson SJ, Tsao EH, Webb BL et al.: X box binding protein XBP-1s transactivates the Kaposis sarcoma-associated herpesvirus (KSHV) ORF50 promoter, linking plasma cell differentiation to KSHV reactivation from latency. J. Virol. 81(24), 13578-13586 (2007).
167. Yu F, Feng J, Harada JN, Chanda SK, Kenney SC, Sun R: B cell terminal differentiation factor XBP-1 induces reactivation of Kaposis sarcoma-associated herpesvirus. FEBS Lett. 581(18), 3485-3488 (2007).
168. Dalton-Griffin L, Wilson SJ, Kellam P: X-box binding protein 1 contributes to induction of the Kaposis sarcoma-associated herpesvirus lytic cycle under hypoxic conditions. J. Virol. 83(14), 7202-7209 (2009).
169. Schroder M, Kaufman RJ: The mammalian unfolded protein response. Annu. Rev. Biochem. 74, 739-789 (2005).
170. Reimold AM, Ponath PD, Li YS et al.: Transcription factor B cell lineage-specific activator protein regulates the gene for human X-box binding protein 1. J. Exp. Med. 183(2), 393-401 (1996).
171. Jenner RG, Maillard K, Cattini N et al.: Kaposis sarcoma-associated herpesvirus-infected primary effusion lymphoma has a plasma cell gene expression profile. Proc. Natl Acad. Sci. USA 100(18), 10399-10404 (2003).
172. Kaletsky RL, Francica JR, Agrawal-Gamse C, Bates P: Tetherin-mediated restriction of filovirus budding is antagonized by the Ebola glycoprotein. Proc. Natl Acad. Sci. USA 106(8), 2886-2891 (2009).
173. Van Damme N, Goff D, Katsura C et al.: The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein. Cell Host Microbe 3(4), 245-252 (2008).
174. Neil SJ, Zang T, Bieniasz PD: Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 451(7177), 425-430 (2008).
175. Mansouri M, Viswanathan K, Douglas JL et al.: Molecular mechanism of BST2/tetherin downregulation by K5/MIR2 of Kaposis sarcoma-associated herpesvirus. J. Virol. 83(19), 9672-9681 (2009).
176. Jia B, Serra-Moreno R, Neidermyer W et al.: Species-specific activity of SIV Nef and HIV-1 Vpu in overcoming restriction by tetherin/BST2. PLoS Pathog. 5(5), E1000429 (2009).
177. Zhang F, Wilson SJ, Landford WC et al.: Nef proteins from simian immunodeficiency viruses are tetherin antagonists. Cell Host Microbe 6(1), 54-67 (2009).
178. Le Tortorec A, Neil SJ: Antagonism to and intracellular sequestration of human tetherin by the human immunodeficiency virus type 2 envelope glycoprotein. J. Virol. 83(22), 11966-11978 (2009).
179. Micheletti F, Monini P, Fortini C et al.: Identification of cytotoxic T lymphocyte epitopes of human herpesvirus 8. Immunology 106(3), 395-403 (2002).
180. Alcami A, Koszinowski UH: Viral mechanisms of immune evasion. Trends Microbiol. 8(9), 410-418 (2000).
181. Ambagala AP, Solheim JC, Srikumaran S: Viral interference with MHC class
182. Coscoy L, Ganem D: Kaposis sarcoma-associated herpesvirus encodes two proteins that block cell surface display of MHC class I chains by enhancing their endocytosis. Proc. Natl Acad. Sci. USA 97(14), 8051-8056 (2000).
183. Ishido S, Wang C, Lee BS, Cohen GB, Jung JU: Downregulation of major histocompatibility complex class I molecules by Kaposis sarcoma-associated herpesvirus K3 and K5 proteins. J. Virol. 74(11), 5300-5309 (2000).
184. Lehner PJ, Hoer S, Dodd R, Duncan LM: Downregulation of cell surface receptors by the K3 family of viral and cellular ubiquitin E3 ligases. Immunol. Rev. 207, 112-125 (2005).
185. Coscoy L: Immune evasion by Kaposis sarcoma-associated herpesvirus. Nat. Rev. Immunol. 7(5), 391-401 (2007).
186. Coscoy L, Sanchez DJ, Ganem D: A novel class of herpesvirus-encoded membrane-bound E3 ubiquitin ligases regulates endocytosis of proteins involved in immune recognition. J. Cell Biol. 155(7), 1265-1273 (2001).
187. Sanchez DJ, Coscoy L, Ganem D: Functional organization of MIR2, a novel viral regulator of selective endocytosis. J. Biol. Chem. 277(8), 6124-6130 (2002).
188. Wang X, Lybarger L, Connors R, Harris MR, Hansen TH: Model for the interaction of gherpesvirus 68 RING-CH finger protein mK3 with major histocompatibility complex class I and the peptide-loading complex. J. Virol. 78(16), 8673-8686 (2004).
189. Lagos D, Trotter MW, Vart RJ et al.: Kaposi sarcoma herpesvirus-encoded vFLIP and vIRF1 regulate antigen presentation in lymphatic endothelial cells. Blood 109(4), 1550-1558 (2007).
190. Goodbourn S, Didcock L, Randall RE: Interferons: cell signalling, immune modulation, antiviral response and virus countermeasures. J. Gen. Virol. 81(Pt 10), 2341-2364 (2000).
191. Li Q, Means R, Lang S, Jung JU: Downregulation of g interferon receptor 1 by Kaposis sarcoma-associated herpesvirus K3 and K5. J. Virol. 81(5), 2117-2127 (2007).
192. Chambers CA, Allison JP: Costimulatory regulation of T cell function. Curr. Opin. Cell Biol. 11(2), 203-210 (1999).
193. Sperling AI, Bluestone JA: The complexities of T-cell co-stimulation: CD28 and beyond. Immunol. Rev. 153, 155-182 (1996).
194. Dustin ML, Springer TA: T-cell receptor cross-linking transiently stimulates adhesiveness through LFA-1. Nature 341(6243), 619-624 (1989).
195. Coscoy L, Ganem D: A viral protein that selectively downregulates ICAM-1 and B7-2 and modulates T cell costimulation. J. Clin. Invest. 107(12), 1599-1606 (2001).
196. Renne R, Dittmer D, Kedes D et al.: Experimental transmission of Kaposis sarcoma-associated herpesvirus (KSHV/ HHV-8) to SIV-positive and SIV-negative rhesus macaques. J. Med. Primatol. 33(1), 1-9 (2004).
197. Parsons CH, Adang LA, Overdevest J et al.: KSHV targets multiple leukocyte lineages during long-term productive infection in NOD/SCID mice. J. Clin. Invest. 116(7), 1963-1973 (2006).
198. Dittmer D, Stoddart C, Renne R et al.: Experimental transmission of Kaposis sarcoma-associated herpesvirus (KSHV/ HHV-8) to SCID-hu Thy/Liv mice. J. Exp. Med. 190(12), 1857-1868 (1999).
199. Foreman KE, Friborg J, Chandran B et al.: Injection of human herpesvirus-8 in human skin engrafted on SCID mice induces Kaposis sarcoma-like lesions. J. Dermatol. Sci. 26(3), 182-193 (2001).
200. Mutlu AD, Cavallin LE, Vincent L et al.: In vivo-restricted and reversible malignancy induced by human herpesvirus-8 KSHV: a cell and animal model of virally induced Kaposis sarcoma. Cancer Cell 11(3), 245-258 (2007). (Pubitemid 46357638)
201. Chang H, Wachtman LM, Pearson CB et al.: Non-human primate model of Kaposis sarcoma-associated herpesvirus infection. PLoS Pathog. 5(10), E1000606 (2009).